Determinants of enrollment in a preventive HIV vaccine trial

被引:141
作者
Buchbinder, SP
Metch, B
Holte, SE
Scheer, S
Coletti, A
Vittinghoff, E
机构
[1] San Francisco Dept Publ Hlth, AIDS Off, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Family Hlth Int, Res Triangle Pk, NC 27709 USA
关键词
HIV vaccine trial; willingness; high-risk; research subject recruitment; enrollment; barriers;
D O I
10.1097/00126334-200405010-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To compare hypothetical and actual willingness to enroll in a preventive HIV vaccine trial and identify factors affecting enrollment. Methods: Participants previously enrolled in an HIV vaccine preparedness study (VPS) in 8 US cities were invited to be screened for a phase 2 HIV vaccine trial. Demographic and risk characteristics of those enrolling, ineligible, and refusing enrollment were compared using the x(2) or Fisher exact test. Multivariable logistic models were used to identify independent predictors of refusal. Results: Of 2531 high-risk HIV-uninfected former VPS participants contacted for the vaccine trial, 13% enrolled, 34% were ineligible, and 53% refused enrollment. Only 20% of those stating hypothetical willingness during the VPS actually enrolled in this vaccine trial. In multivariate analysis, refusal was higher among African Americans and lower in persons >40 years of age, those attending college, and those with greater than or equal to5 partners in the prior 6 months. All racial ethnic groups cited concerns about vaccine-induced seropositivity; African Americans also cited mistrust of government and safety concerns as barriers to enrollment. Conclusions: Steps can be taken to minimize potential social harms and to mobilize diverse communities to enroll in trials. Statements of hypothetical willingness to participate in future trials may overestimate true enrollment.
引用
收藏
页码:604 / 612
页数:9
相关论文
共 45 条
[1]   Trial-related discrimination in HIV vaccine clinical trials [J].
Allen, M ;
Israel, H ;
Rybczyk, K ;
Pugliese, MA ;
Loughran, K ;
Wagner, L ;
Erb, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (08) :667-674
[2]  
Baeten JM, 2000, J ACQ IMMUN DEF SYND, V24, P458, DOI 10.1097/00126334-200008150-00011
[3]   Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men [J].
Bartholow, BN ;
MacQueen, KM ;
Douglas, JM ;
Buchbinder, S ;
McKirnan, D ;
Judson, FN .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (02) :108-115
[4]  
BARTHOLOW BN, 2002, 14 INT AIDS C BAR
[5]   Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers [J].
Belshe, RB ;
Stevens, C ;
Gorse, GJ ;
Buchbinder, S ;
Weinhold, K ;
Sheppard, H ;
Stablein, D ;
Self, S ;
McNamara, J ;
Frey, S ;
Flores, J ;
Excler, JL ;
Klein, M ;
El Habib, R ;
Duliege, AM ;
Harro, C ;
Corey, L ;
Keefer, M ;
Mulligan, M ;
Wright, P ;
Celum, C ;
Judson, F ;
Mayer, K ;
McKirnan, D ;
Marmor, M ;
Woody, G .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (09) :1343-1352
[6]   INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS [J].
BELSHE, RB ;
CLEMENTS, ML ;
KEEFER, MC ;
GRAHAM, BS ;
COREY, L ;
SPOSTO, R ;
WESCOTT, S ;
LAWRENCE, D ;
GORSE, GJ ;
KENNEDY, D ;
FREY, S ;
LAMBERT, J ;
SCHWARTZ, D ;
DOLIN, R ;
ROBERTS, N ;
MCELRATH, J ;
COOMBS, J ;
WRIGHT, P ;
KARZON, D ;
FAST, P ;
WALKER, MC ;
MESTECKY, J ;
JACKSON, S ;
STABLEIN, D ;
WOLFF, M .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (08) :584-+
[7]   Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: Risk behavior, seroincidence, and willingness to participate [J].
Buchbinder, SP ;
Douglas, JM ;
McKirnan, DJ ;
Judson, FN ;
Katz, MH ;
MacQueen, KM .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :954-961
[8]   WILLINGNESS TO PARTICIPATE IN AIDS VACCINE TRIALS AMONG HIGH-RISK POPULATIONS IN NORTHERN THAILAND [J].
CELENTANO, DD ;
BEYRER, C ;
NATPRATAN, C ;
EIUMTRAKUL, S ;
SUSSMAN, L ;
RENZULLO, PO ;
KHAMBOONRUANG, C ;
NELSON, KE .
AIDS, 1995, 9 (09) :1079-1083
[9]   Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note [J].
Chesney, MA ;
Chambers, DB ;
Kahn, JO .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (04) :266-271
[10]   THE CHALLENGE OF MINORITY RECRUITMENT IN CLINICAL-TRIALS FOR AIDS [J].
ELSADR, W ;
CAPPS, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (07) :954-957